adcs

The boys discuss Patch 14.3, the state of ADCs, Overreactions of Smolder, and more all on episode 626 of Leaguecast!

Email us - mail@leaguecastpodcast.com  

Support us - https://www.patreon.com/leaguecast 

Tweet us - https://twitter.com/leaguecast  

Facebook - https://www.facebook.com/Leaguecast/  

Join Our Discord - https://discord.gg/leaguecast 

Visit our Website - https://leaguecastpodcast.com/

In the second episode of the Cancer Nurses Society of Australia podcast series, we discuss Antibody- Drug Conjugates (ADCs) . ADCs are a new type of cancer treatment that combines the targeting ability of antibodies with the potency of chemotherapy drugs. Justin Hargreaves Medical Oncology Nurse Practitioner, Bendigo Health Cancer Centre and Chair of the CNSA Specialist Practice Network is joined by Gillian Kruss, Metastatic Breast Cancer Nurse Practitioner at Monash Health and Marissa Stevens, Oncology Nurse Practitioner at St Vincent’s Hospital in Melbourne, to discuss the latest advances in ADC therapy and specifically the nursing management of metastatic triple negative breast cancer patients who are receiving Trodelvy (Sacituzumab govitecan).

🤖 Tiny Robot Bees: The buzzworthy future of pollination and surveillance
Rolls Royce's lunar leap: A green light for building nuclear reactors on the moon
GPT-4 & MidJourney 5: The dawn of a new era in artificial intelligence and machine learning
Microsoft AI's EVERYTHING: A glimpse into the omnipresence of AI in everything Microsoft offers
Pfizer's $43 Billion Biotech Bonanza: The acquisition of Seagen and what it means for the industry
T-Mobile & Mint Mobile: Ryan Reynolds' $1.35B deal to shake up the wireless market

🚀 Main Topic: The Future of Silicon Valley - Big Tech Bloodbaths, Billionaires & Bailouts:SVB: Unpacking the Silicon Valley Bank Bailout 
Meta's massive layoffs: 10,000 more workers lose jobs following 11,000 cuts four months ago
Billionaire tech visionaries: Mark Zuckerberg, Elon Musk, Jeff Bezos, Bill Gates, and Jack Dorsey - Are they shaping our future or are they out of touch psychopaths?

Don't miss out on our engaging conversation as we explore the latest developments in the tech world and debate the future of Silicon Valley. Be sure to like, comment, and subscribe to stay updated on all our episodes!

#SiliconValley #BigTech #Billionaires #Meta #RollsRoyce #ArtificialIntelligence #Pfizer #TMobil #MintMobile #Podcast

Financially Support the Show with Super Chats or Patreon: patreon.com/thesingularitylab

Follow Us:

Follow Michael Mataluni: https://linktr.ee/michaelmataluni​
Follow Brooks Lopez: https://twitter.com/StrivinToThrive
Follow Randy: https://twitter.com/randolphmorley

𝐒𝐔𝐁𝐒𝐂𝐑𝐈𝐁𝐄 𝐓𝐎 𝐒𝐓𝐀𝐘 𝐔𝐏 𝐓O 𝐃𝐀𝐓𝐄

______________________________________

►Link Tree: https://linktr.ee/michaelmataluni​

► YouTube: https://www.youtube.com/@TheSingularityLab

►Apple Podcast: https://podcasts.apple.com/us/podcast...
►Spotify: https://open.spotify.com/show/1gE7LEI...
►Twitter: https://twitter.com/singularitymike
►Instagram: https://www.instagram.com/thesingular...
►Facebook: https://www.facebook.com/mataluni/
►Page: https://www.facebook.com/michaelmataluni
►Discord: https://discord.gg/J2AQxqjusv

Ovarian malignant tumor is one of the common malignant tumors of female reproductive organs, and its incidence rate ranks third only after cervical cancer and endometrial cancer. However, the mortality of ovarian epithelial cancer accounts for the first place in all kinds of gynecological tumors, posing a serious threat to women's lives. It is therefore critical to ensure that the ADC releases the drug while it is still extracellular. To achieve this goal, Tagworks has designed a smart ADC that binds to cancer receptors when injected into the body, and after 1-2 days, the cells are enriched with ADCs. Robillard said: "Our innovation is that we use a second component that can 'click release' chemotherapy drugs from the ADC. The result is a large number of chemotherapy drugs that release quickly and attack the tumor. This method is promising for a variety of treatments. "
https://www.creative-biolabs.com/adc/services.htm

Antibody-drug conjugates selectively and continuously deliver cytotoxic drugs to tumors. Its three main components are antibodies, cytotoxic agents and linkers. Many monoclonal antibodies are standard therapies for solid tumors and hematological cancers, while primary chemotherapy drugs have limited therapeutic effects on cancer due to their non-specific toxicity. The discovery of ADC fills the gap between the two. Mylotarg is the first FDA approved ADC for acute myeloid leukemia. Adcetris is a conjugate of the CD30 antibody and monomethyl auristatin E and is approved for the treatment of lymphoma. Kadcyla has been commercialized for HER-2 positive metastatic breast cancer. The challenges faced by ADCs include antibody immunogenicity, antigen expression, premature drug release, etc. Progress in bioengineering has improved its safety and efficacy.
https://www.creative-biolabs.com/adc/services.htm